Feng is a Professor in the Department of Immunology and Immunity at Case Western University and a Staff Scientist at the Lerner Research Institute of the Cleveland Clinic. He has over 20 years of experience in studying immunology with more than 10 years of experience studying CD6 and its role in autoimmunity. This work led to his discovery of new therapeutic properties of the monoclonal antibody that targets CD6 with Dr. David Fox and the creation of ATX101, the antibody-drug complex being developed by Abcon, the Company he founded in 2020. Feng is the PI of both of Abcon’s STTR grants and has received over $20M from the NIH for research at his academic labs. He has authored or co-authored almost 100 peer-reviewed manuscripts.
